Mobia Medical (NASDAQ:MOBI) Director Purchases $198,442.87 in Stock

Mobia Medical, Inc. (NASDAQ:MOBI) Director Casey Tansey acquired 16,441 shares of Mobia Medical stock in a transaction that occurred on Tuesday, August 18th. The stock was acquired at an average price of $12.07 per share, with a total value of $198,442.87. Following the completion of the acquisition, the director directly owned 318,332 shares in the company, valued at $3,842,267.24. This represents a 5.45% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Mobia Medical Stock Performance

Shares of NASDAQ:MOBI opened at $10.61 on Friday. The company has a current ratio of 13.28, a quick ratio of 12.80 and a debt-to-equity ratio of 0.04. The stock has a market cap of $353.21 million and a price-to-earnings ratio of -0.53. The stock has a 50-day simple moving average of $12.31. Mobia Medical, Inc. has a fifty-two week low of $10.19 and a fifty-two week high of $15.29.

Mobia Medical (NASDAQ:MOBI) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.27). The firm had revenue of $13.51 million for the quarter. The business’s revenue was up 102.4% compared to the same quarter last year. As a group, research analysts predict that Mobia Medical, Inc. will post -2.76 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on MOBI shares. Bank of America began coverage on shares of Mobia Medical in a report on Tuesday, June 2nd. They issued a “buy” rating and a $16.00 target price on the stock. The Goldman Sachs Group began coverage on Mobia Medical in a report on Tuesday, June 2nd. They set a “buy” rating and a $31.00 price target on the stock. Weiss Ratings started coverage on Mobia Medical in a research note on Wednesday, August 12th. They issued a “sell (e-)” rating on the stock. Wolfe Research assumed coverage on Mobia Medical in a report on Tuesday, June 2nd. They issued an “outperform” rating for the company. Finally, Wall Street Zen upgraded Mobia Medical from a “sell” rating to a “hold” rating in a research report on Sunday, June 14th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $20.75.

Mobia Medical Company Profile

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.